DHL Group has unveiled plans to invest €2 billion over the next five years to boost its logistics capabilities in the life sciences and healthcare sector, aligning with its “Strategy 2030” vision. This major investment underscores DHL’s commitment to supporting healthcare companies in delivering faster, more reliable, and patient-centric supply chain solutions globally.
The investment will be distributed with 50% allocated to the Americas, and 25% each to the Asia Pacific and EMEA regions. It will fund the development of high-quality infrastructure and advanced technologies across the entire logistics chain—from storage and order fulfillment to global shipping and last-mile delivery.
Key areas of focus include the expansion of GDP-certified Pharma Hubs for multi-temperature shipments, increased cold chain capacity, new temperature-controlled vehicles, and enhanced sustainable packaging solutions. The initiative also supports growing demand in specialized fields such as clinical trials, biopharma, and cell and gene therapies, with added investment in ultra-low temperature cooling infrastructure.
Advanced IT systems will be implemented to offer end-to-end supply chain visibility, ensuring regulatory compliance and the safe, reliable delivery of sensitive healthcare products.
To unify its efforts under a single identity, DHL has launched a new sector brand—DHL Health Logistics—bringing together its life sciences and healthcare expertise. This brand will provide an integrated, streamlined experience for pharmaceutical, biopharma, and medical customers, designed to meet their evolving need for agile and connected logistics solutions.